Gubra AS (GUBRA)

Currency in DKK
357.00
-4.40(-1.22%)
Closed·
GUBRA Scorecard
Full Analysis
Net income is expected to grow this year
High dividend Yield
GUBRA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
357.00369.80
52 wk Range
323.40748.00
Key Statistics
Prev. Close
361.4
Open
363.6
Day's Range
357-369.8
52 wk Range
323.4-748
Volume
20.77K
Average Volume (3m)
45.58K
1-Year Change
-42.42%
Book Value / Share
27.63
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GUBRA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
635.00
Upside
+77.87%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Gubra AS News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Gubra AS Company Profile

Gubra A/S, a biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally. The company operates through three segments: Pre-Clinical Contract Research (CRO), Discovery & Partnerships, and Gubra Green. It offers pre-clinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, pharmacokinetics, and 2D and 3D histology with artificial intelligence pathology. The company has partnership and collaboration with Boehringer Ingelheim for the treatment of obesity; Hemab ApS to treat bleeding disorders; and Amylyx Pharmaceuticals, Inc. to develop a novel long-acting GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseases. Gubra A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Gubra AS Earnings Call Summary for Q1/2025

  • Gubra reports Q1 2025 results: $350M upfront from AbbVie deal, potential $1.875B in milestones; stock rises 2.6%
  • GUPAMI program shows promising weight loss results; UCN2 obesity program first-in-human study planned for early 2026
  • CRO revenue slightly down YoY, but company maintains 20% growth guidance for full-year 2025
  • Management evaluating M&A opportunities; analysts project strong sales growth and EPS of $18.04 for FY2025
  • Slight decline in CRO revenue and longer US decision times pose challenges; focus shifts to quality of weight loss in treatments
Last Updated: 09/05/2025, 09:30
Read Full Transcript

Compare GUBRA to Peers and Sector

Metrics to compare
GUBRA
Peers
Sector
Relationship
P/E Ratio
−159.5x−2.7x−0.5x
PEG Ratio
−6.72−0.010.00
Price/Book
12.9x1.2x2.6x
Price / LTM Sales
21.9x1.9x3.3x
Upside (Analyst Target)
77.9%100.0%43.5%
Fair Value Upside
Unlock16.0%6.8%Unlock

Analyst Ratings

1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 635.00
(+77.87% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -2.24%
Dividend Yield
17.14%
Industry Median 100.88%
Annualised payout
61.20
Paid unevenly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
May 09, 2025
EPS / Forecast
-- / --
Revenue / Forecast
57.50M / --
EPS Revisions
Last 90 days

GUBRA Income Statement

People Also Watch

229.00
TCFP
-0.95%
616.90
ASML
+1.02%
1,620.500
RHMG
-1.25%
9.876
TKAG
+2.68%
323.1
NOVOb
+4.60%

FAQ

What Stock Exchange Does Gubra AS Trade On?

Gubra AS is listed and trades on the Copenhagen Stock Exchange stock exchange.

What Is the Stock Symbol for Gubra AS?

The stock symbol for Gubra AS is "GUBRA."

What Is the Gubra AS Market Cap?

As of today, Gubra AS market cap is 5.82B.

What Is Gubra AS's Earnings Per Share (TTM)?

The Gubra AS EPS (TTM) is -2.24.

When Is the Next Gubra AS Earnings Date?

Gubra AS will release its next earnings report on 06 Nov 2025.

From a Technical Analysis Perspective, Is GUBRA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Gubra AS Stock Split?

Gubra AS has split 0 times.

How Many Employees Does Gubra AS Have?

Gubra AS has 260 employees.

What is the current trading status of Gubra AS (GUBRA)?

As of 09 Aug 2025, Gubra AS (GUBRA) is trading at a price of 357.00, with a previous close of 361.40. The stock has fluctuated within a day range of 357.00 to 369.80, while its 52-week range spans from 323.40 to 748.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.